Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 241

The DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.

Prostate-Specific Membrane Antigen Ligands for Imaging and Therapy

Open access
Eiber, Matthias, Fendler, Wolfgang P., Rowe, Steven P., Calais, Jeremie, Hofman, Michael S., Maurer, Tobias, Schwarzenboeck, Sarah M., Kratowchil, Clemens, Herrmann, Ken, Giesel, Frederik L.·2017·Journal of Nuclear Medicine

Abstract

The prostate-specific membrane antigen (PSMA) is highly expressed on most prostate cancer (PC) cells. Therefore, the targeting of PSMA has become increasingly important over the last decade. Glu-urea–based PSMA ligands used for both imaging and radioligand therapy are the mainstays of the current success. For PET imaging, both 68Ga- and 18F-labeled agents have been successfully translated to clinical applications. Mainly retrospective cohort studies have shown a high value in the setting of biochemical recurrence, with high detection rates even in the presence of low prostate-specific antigen levels. Preliminary data indicated that radioguided surgery with PSMA ligands may help to further improve patient outcomes because it facilitates the removal of small tumor deposits that are otherwise difficult to detect. For primary PC, PSMA ligand PET imaging has been shown to be superior to cross-sectional imaging for the detection of metastatic lymph nodes. In addition, it promises to also provide intraprostatic tumor localization, especially when used in combination with multiparametric MRI. Increasing numbers of studies have reported considerable changes in management resulting from PSMA ligand PET imaging for both biochemical recurrence and primary disease. The use of 177Lu-PSMA–based radioligand therapy has demonstrated a reasonable response, mainly as defined by a prostate-specific antigen response of more than 50%, comparable to other recently introduced agents. Especially given the high level of safety of 177Lu-PSMA radioligand therapy, with only minimal grade 3 and 4 toxicities reported so far, it has the potential to expand options for metastatic castration-resistant PC. This review is intended to provide a comprehensive overview of the current literature on low-molecular-weight PSMA ligands for both PET imaging and therapeutic approaches, with a focus on agents that have been clinically adopted.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.2967/jnumed.116.186767

Cites

8 of 8 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 8 references

Cited by

See all 241

Metadata

Authors
Eiber, M., Fendler, W. P., Rowe, S. P., Calais, J., Hofman, M. S., Maurer, T., Schwarzenboeck, S. M., Kratowchil, C., Herrmann, K., & Giesel, F. L.
Venue
Journal of Nuclear Medicine
Published
2017-09
Volume
58
Issue
Supplement 2
Pages
67S-76S
ISSN
  • 0161-5505 (ISSN-L)
  • 2159-662X
OpenAlex
W2752389930
Cited by
241
References
8
FWCI
19.12
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Prostate-Specific Membrane Antigen Ligands for Imaging and Therapy. https://app.cochat.ai/papers/10.2967/jnumed.116.186767
The paper
Eiber, M., Fendler, W. P., Rowe, S. P., Calais, J., Hofman, M. S., Maurer, T., Schwarzenboeck, S. M., Kratowchil, C., Herrmann, K., & Giesel, F. L. (2017). Prostate-Specific Membrane Antigen Ligands for Imaging and Therapy. Journal of Nuclear Medicine. https://doi.org/10.2967/jnumed.116.186767

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.